Page 71 - Heart Transplant Protocol

Heart Function Service: Heart Transplant Protocols

4. Hohlfeld R. Dalakas MC. Semin Neurol. 2003 Jun;23(2):121-32. Basic principles of immunotherapy
for neurologic diseases.
5. Journal of the Peripheral Nervous System. Volume 8 Issue 4 Page 282 – December 2003,
doi:10.1111/j.1085-9489.2003.03031.x.
6. Lang B. Duffy C. Controversies in the management of Kawasaki disease. Best Practices and
Research Clinical Rheumatology 2002; vol. 16(3): 427-42.
7. Nowak-Wegrzyn A. Lederman H. Supply. Use and abuse of intravenous immunoglobulin. Current
Opinion in Pediatrics December 1999; vol. 11 (6): 533
8. Obando, et al. Aseptic meningitis due to administration of intravenous immunoglobulin with an
unusually high number of leukocytes in cerebrospinal fluid. Pediatric Emergency Care 2002; vol.
18(6): 429-32
9. Schiff RI, Williams LW, Nelson RP, Buckley RH, Burks W, Good RA. Multicenter crossover
comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and
Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol. 1997 Jan;
17(1);21-8.

Attachment A

IVIG Indications and Suggested Dosing

IVIG therapy indications and usual doses are as follows:

 Primary and secondary immunodeficiency diseases-
o Initial- 200 to 400 milligrams (mg)/kilogram (kg)/dose
o Increase dose and frequency to maintain IgG concentration >500 mg/dL
o Maintenance – 100 to 400 mg/kg/dose
 Gullian-Barre
o 400-1000 mg/kg/daily times 5 days
 Kawasaki syndrome – Single dose of 2000 mg/kg with concurrent aspirin therapy
 Bone marrow transplant recipients with recurrent infections
o 400-500 mg/kg/dose monthly
o Increase dose and frequency to maintain IgG concentration >400 mg/dL
 Idiopathic thrombocytopenic purpura-
o Single dose – 1000 mg/kg/dose
o Up to 3 separate doses on alternate days may be required
 HIV infected patients with hypogammaglobinemia
o 400 mg/kg/dose monthly
 Neurological Diseases-
o Acute and chronic autoimmune polyneuropathy
o Myasthenia Gravis relapse
o Poly/dermatomyosits refractory to oral steroids and azathioprine
o Sydenham’s chorea refractory to both pulse methylprednisolone (PMP) and Valproic
acid
o Opsoclonus Myoclonus syndrome refractory to PMP

Updated November 9, 2017 71